Cardiac Cachexia in Advanced Heart Failure
NCT06259045
Advanced Heart Failure, Body Weight
London, United Kingdom
View Trial DetailsNCT Number: NCT00690157
Main goal of the study is the risk stratification of patients with advanced heart failure referred for orthotopic heart transplantation (OHT) according to HFSS score, other risk factors and biological markers and verification of their prognostic value in Polish population.
Looking for future studies?
Notify Me10 year and older
All sexes
Observational
Klinika Chirurgii Serca, Naczyń i Transplantologii, Szpital im.Jan Pawłą II, Krakow, Poland
PART I 23.10.2008- 31.12.2005 Creation of the Polish national registry of patients referred for cardiac transplantation and after heart transplantation - including urgency of qualification and prognosis.
Main goal of the study is the risk stratification of patients with advanced heart failure referred for orthotopic heart transplantation (OHT) according to HFSS score, other risk factors and biological markers and verification of their prognostic value in Polish population.
All patients with advanced heart failure referred as potential candidates for OHT in all active transplantation centers were included in the registry.
PART II 1.01.2006 -30.11.2007 Since 2006 only patients which were definitely enlisted on the waiting list for heart transplantation were included in the registry
Clinical and laboratory data were recorded in the internet based form. Clinical data included the etiology of the disease, NYHA class, duration of symptoms pharmacological therapy, left ventricular ejection fraction, Ergospirometric maximal oxygen uptake (V02 max) results and right heart catheterization results , ecg data of leading heart rhythm and QRS duration >=0,12 s and other were stored Sodium ,NTproBNP levels and hs CRP plasma levels were recorded during first 48 hours of hospitalization. All patients were followed in a prospective cohort study until the end point : death or OHT , observations were censored at the end of the study. The urgency of OHT and death data was recorded by information from participating centers and national death registry quarries.
Primary end point : Death for all causes or urgent (UNOS 1) heart transplantation Secondary end point: Death without transplantation Death or heart transplantation
Substudy POLKARD HF registry - genetic polymorphism substudy Study start date 01.04.2004 end 30.10.2007
Study population: All consecutive patients included into POLKARD HF registry, who agreed to participate and signed ICF related to the substudy.
Estimated size 350 - 450 patients.
Aims: To describe the potential impact of selected candidate genes polymorphisms on the heart failure prognosis and the survival of patients after orthotropic heart transplantation
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: prospective progressive 1 to 48 months
Time frame: prospective , progressive 1 to 48 months
National Institute of Cardiology, Warsaw, Poland
Other
National Polish Registry of Patients Referred for Heart Transplantation. POLKARD HF
Acronym: POLKARD HF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06259045
Advanced Heart Failure, Body Weight
London, United Kingdom
View Trial DetailsNCT01210573
Advanced Heart Failure, Cardiovascular Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT01643551
Advanced Heart Failure, Cardiovascular Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT07632586
Advanced Heart Failure, Cardiovascular Diseases
Prague, Czechia
View Trial Details